BIOCHEMICAL-COMPARISON OF INTERMITTENT STREPTOKINASE AND INTERMITTENT STREPTOKINASE PLASMINOGEN THERAPY

被引:4
作者
BARLOW, GH
KAKKAR, VV
BENTLEY, PG
CHAN, PS
JONES, NAG
MISTRY, FD
机构
[1] Thrombosis Research Unit, King's College Hospital Medical School, London, Denmark Hill
基金
英国医学研究理事会;
关键词
D O I
10.1016/0049-3848(79)90059-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A comparison has been made of some biochemical parameters during streptokinase and streptokinase combined with lys-plasminogen intermittent therapies using a twice a day dosing regimen. Results showed that while the fibrinogen levels, fibrin(ogen) degradation products and total fibrinolytic activity appeared very similar there was a pronounced difference in the effect on antiplasmin levels and on the amount of activator complex formed. With the combination therapy the antiplasmin levels fell to zero and remained at zero throughout the therapy while the level returned daily to approximately 50% of normal with the streptokinase alone regimen. The amount of activator complex formed was much higher in the combination therapy and this could explain the lessened side effects observed in this type of therapy. © 1979.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 15 条
  • [1] AMERY A, 1969, ACTIVATION HUMAN FIB
  • [2] ASTRUP P, 1952, ARCH BIOCH BIOPHYS, V46, P346
  • [3] BARLOW GH, 1975, RES COMMUN CHEM PATH, V10, P465
  • [4] IMMUNOLOGICAL COMPARISON OF NATIVE STREPTOKINASE WITH STREPTOKINASE FRAGMENTS
    BARLOW, GH
    FINLEY, R
    CASTELLINO, FJ
    [J]. THROMBOSIS RESEARCH, 1976, 8 (02) : 237 - 242
  • [5] BLOMBACK B, 1956, ARK KEMI, V10, P415
  • [6] FRIBERGER P, 1978, CHROMOGENIC SUBSTRAT
  • [7] HARDISTY RM, BLEEDING DISORDERS
  • [8] KAKKAR VV, 1975, LANCET, V2, P674
  • [9] REDDY K N N, 1974, Journal of Biological Chemistry, V249, P4851
  • [10] SCULLY MF, 1977, THROMB HAEMOSTASIS, V37, P162